In response to Hurricane Milton, some of our operations have changed for the safety of our patients, their loved ones and our team members.
Free In-App Video Visits for Floridians
From 8 am Wednesday through 8 pm Thursday, Floridians can use code “Milton” for free urgent care Video Visits in the AdventHealth app. Test link
Extra Safety Measures for Your Protection
Your health and safety have always been our top priority and we have expanded our policies, procedures and products to protect you and our caregivers. These safety measures include enhanced cleaning and sanitation, universal mask use, temperature checks, social distancing, visitor restrictions and keeping COVID-19 symptomatic patients separated from other patients. Details here
For continuous updates on the status of our facility and the residents in our care, please call our coronavirus information hotline at 407-776-6009.
AdventHealth Part of First and Only Treatment Approved by the FDA to Delay the Onset of a Stage of Type 1 Diabetes
The Food and Drug Administration (FDA) recently approved a new drug to treat Type 1 diabetes and AdventHealth contributed to the large global screening effort that make groundbreaking studies like this possible. Now, AdventHealth is one of a handful of hospital systems approved to distribute this medication.
This breakthrough treatment, called TZIELD, is the first drug that can delay the progression of Type 1 diabetes by up to three years in adults and up to eight years in children. To determine eligibility for the treatment, a simple blood test is performed. If the blood test is positive, then an oral glucose tolerance test is administered to see if the blood glucose is increasing.
Dr. Casu is an associate investigator in Type 1 diabetes research at the AdventHealth Translational Research Institute.
“For the first time, a disease we thought was inevitable, can now be delayed,” said Anna Casu, MD, associate investigator in Type 1 diabetes research at the AdventHealth Translational Research Institute. “Now there’s a reason for screening for Type 1 diabetes because its burden can be delayed. This innovation drives me to continue our research to uncover a cure.”
The study, leading to TZIELD approval, was conducted by the Type 1 Diabetes TrialNet Consortium, which screened roughly 200,000 participants for Type 1 diabetes. AdventHealth served as a screening site.
Dr. Reddy is the medical director of Pediatric Endocrinology and Diabetes at AdventHealth for Children.
“Diabetes is a disease that never goes away, so a delayed diagnosis with treatment like this drug can have a significant impact on quality of life for the patient and their family,” said Konda M. Reddy, MD, medical director of Pediatric Endocrinology and Diabetes at AdventHealth for Children. “This is a historic moment for the Type 1 diabetes community. It means there’s more time to live without the burden of the disease and complications.”
Type 1 diabetes is a disease that occurs when the immune system attacks and destroys the cells that make insulin. According to the Juvenile Diabetes Research Foundation, some 1.45 million Americans are living with Type 1 diabetes and 64,000 are diagnosed each year in the U.S.
Patients or referring physicians who are interested in starting the screening process, please contact Dr. Reddy’s office at Call407-896-2901.
Recent News
12 items. To interact with these items, press Control-Option-Shift-Right Arrow. These items are in a slider. To advance slider forward, press Shift-Command-Right Arrow. To advance slider backward, press Shift-Command-Left Arrow.
Our website uses cookies. Please review our privacy policy to find out more about the cookies we use. Browsing our website means you accept these terms.
